Bardet-Biedl Syndrome

Etiology

BBS is inherited in an autosomal recessive pattern. At least 26 genes have been definitively associated with the condition, each encoding a protein that localizes primarily to the basal body, centrosome, or primary cilium.[2] The BBSome, an octameric coat-like complex composed of BBS1, BBS2, BBS4, BBS5, BBS7, BBS8 (TTC8), BBS9, and BBS18 (BBIP1), mediates selective intraflagellar transport of G-protein-coupled receptors within the ciliary membrane. These receptors include the melanocortin-4 receptor (MC4R) and leptin receptor, both of which are central to appetite regulation and energy homeostasis. A second group of BBS proteins, including BBS6 (MKKS), BBS10, and BBS12, functions as chaperonin-like proteins that facilitate BBSome assembly.[5]

Pathogenic variants in BBS1 account for approximately 23% to 43% of cases, depending on the cohort, and the p.M390R missense variant is the most prevalent BBS1 allele in individuals of Northern European ancestry. BBS10 is the second most commonly implicated gene, accounting for approximately 25% of positive findings in the Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS).[2] An oligogenic or modifier inheritance model has been proposed in selected kindreds, in which secondary variants in additional BBS-associated or ciliary genes appear to influence penetrance and severity. However, classical biallelic recessive inheritance at a single locus remains the predominant mechanism.[6] Founder effects have been described in several genetically isolated populations, including Bedouin communities in the Middle East, the Faroe Islands, Newfoundland, and the island of La Réunion, contributing to regionally elevated prevalence.[3]

Epidemiology

BBS affects approximately 1 in 100,000 to 1 in 160,000 individuals in North American and European populations. Prevalence is substantially higher in genetically isolated communities, reaching approximately 1 in 13,500 to 1 in 17,500 among Bedouin populations of Kuwait and the wider Middle East, and approximately 1 in 17,500 in Newfoundland, Canada. An estimated 1,500 to 2,500 individuals are affected in the United States.[3] 

BBS affects males and females in equal proportions, with no established sex predilection. Diagnosis most commonly occurs in childhood. A recent multicountry cohort study reported a median age at confirmed diagnosis of approximately 9 years, reflecting the progressive nature of the syndrome and the variable age at which individual features become clinically apparent. The global burden of BBS is likely underestimated, particularly in low- and middle-income countries, where underrecognition of clinical features and limited access to molecular genetic testing contribute to underdiagnosis.[2]

Pathophysiology

BBS is a primary nonmotile ciliopathy that arises from dysfunction of proteins required for ciliary biogenesis, intraflagellar transport, and receptor trafficking at the primary cilium.[5] Although primary cilia are present on nearly every cell type in the human body, the clinical manifestations of BBS reflect the tissues in which ciliary signaling is most physiologically essential, including the hypothalamus, kidney, retina, and developing limb. Disruption of BBSome function impairs ciliary trafficking of the leptin receptor to the surface of hypothalamic arcuate nucleus pro-opiomelanocortin (POMC) neurons.

The resulting attenuation of leptin signaling leads to deficient release of alpha-melanocyte-stimulating hormone (α-MSH), the endogenous agonist of the melanocortin-4 receptor (MC4R) in the paraventricular nucleus. Impaired MC4R activation in turn produces severe, early-onset hyperphagia and obesity that is pathobiologically distinct from common polygenic obesity and is largely refractory to conventional dietary and lifestyle management. This mechanism provides the biological rationale for setmelanotide, an MC4R agonist that bypasses the upstream signaling defect.[2] 

In the kidney, ciliary dysfunction within tubular epithelial cells disrupts tubulogenesis and mechanosensory flow detection, contributing to structural anomalies including cortical and medullary cysts, calyceal malformations, and parenchymal dysplasia. These changes can progress over time to chronic kidney disease and, in a subset of patients, to kidney failure requiring renal replacement therapy. In the retina, failure of ciliary transport across the photoreceptor connecting cilium leads to mislocalization of opsins and progressive rod-cone dystrophy, beginning with rod-mediated night blindness in childhood and progressing to cone involvement, peripheral and central visual field loss, and, in most patients, legal blindness by the second or third decade of life.[3] 

History and Physical

Per the 2026 updated consensus diagnostic criteria proposed by Pomeroy and colleagues, clinical manifestations are categorized into 6 major criteria and 8 minor criteria (see Image. Diagnostic Criteria for Bardet-Biedl Syndrome). A clinical diagnosis of BBS is supported by the presence of either 4 major criteria or 3 major criteria plus 2 minor criteria. Importantly, the absence of any single criterion does not exclude the diagnosis, because not all manifestations are present in every patient, and the age of onset varies considerably across organ systems.[2]

Major Criterion 1: Retinal Dystrophy

Retinal dystrophy is the most consistent feature across genotypes and is present in approximately 76% to 97% of individuals, with prevalence increasing with age. BBS-related retinal disease manifests predominantly as a rod-cone dystrophy. Early rod-mediated symptoms include nyctalopia, which is typically apparent by 7 to 8 years of age, and progressive peripheral visual field constriction. These findings later progress to cone dysfunction with reduced central visual acuity and color discrimination. Additional early features, eg, scotopic adaptation defects, blurred or distorted vision, and nystagmus, should prompt formal ophthalmologic evaluation, including electroretinography. Legal blindness commonly develops between the second and fourth decades of life.[2][1] 

Major Criterion 2: Obesity or Overweight

Obesity is present in approximately 87% to 89% of individuals with BBS and typically begins within the first few years of life. Obesity at any age qualifies as a major criterion, defined as a body mass index (BMI) of 30 kg/m² or greater in adults, and a BMI at or above the 95th percentile for age and sex in pediatric patients 2 years and older. In children younger than 2 years, weight-for-length at or above the 85th percentile is considered a major criterion, enabling earlier recognition. Hyperphagia, characterized by abnormal food-seeking behaviors, inability to achieve satiety, and persistent preoccupation with food, is present in nearly all affected individuals. However, hyperphagia is not itself counted as a separate diagnostic criterion because no standardized, validated assessment tool is currently in routine clinical use.[2][7] 

Major Criterion 3: Congenital Anomalies of the Kidney and Urinary Tract or Chronic Kidney Disease

Renal involvement is present in approximately 26% to 81% of patients, depending on the specific anomaly assessed, and chronic kidney disease (CKD) is reported in 31% to 39% of affected individuals. Congenital anomalies of the kidney and urinary tract (CAKUT) in BBS encompass renal hypoplasia or agenesis, renal cysts, fetal lobulation, caliectasis, calyceal clubbing, loss of renal corticomedullary differentiation, and ectopic kidney. When both CAKUT and CKD are present in the same patient, they are counted only once toward the diagnostic threshold. Advanced CKD progressing to kidney failure requiring dialysis or transplantation occurs in approximately 6% to 7% of patients and represents a major contributor to BBS-associated morbidity and mortality.[2][8]

Major Criterion 4: Hypogonadism or Genital Anomalies

Hypogonadism or genital anomalies are present in approximately 34% to 68% of patients and are counted once when both are present. In males, findings include micropenis (approximately 70%), cryptorchidism (approximately 26% to 28%), and delayed puberty. In females, findings include vaginal atresia (approximately 14% to 22%), hydrocolpos or hydrometrocolpos (approximately 8% to 35%), hypoplastic or duplex uterus, and persistent urogenital sinus. These features may be the earliest recognized manifestations in the neonatal period and warrant prompt evaluation by pediatric urology and endocrinology.[2]

Major Criterion 5: Neurodevelopmental and Cognitive Manifestations

Neurodevelopmental and cognitive manifestations are present in approximately 67% to 72% of individuals and are formally recognized as a major diagnostic criterion in the 2026 framework. This represents a meaningful update from prior criteria and reflects both the high prevalence and the diagnostic value of these features. They are counted only once regardless of the number of associated manifestations identified in a given patient.

Specific findings include delays in expressive language and fine motor development, intellectual disability (Full Scale IQ consistent with intellectual disability in 20% to 58% of patients), features of autism spectrum disorder (approximately 35.6% screen positive, with 17% receiving a formal diagnosis), and imbalance or ataxia. The absence of neurodevelopmental dysfunction does not preclude a BBS diagnosis.[2]

Major Criterion 6: Postaxial Polydactyly

Postaxial polydactyly is present in approximately 75% to 79% of individuals with BBS. Postaxial polydactyly may be symmetrical or asymmetrical and may affect 1 or more extremities. This finding is most often identified prenatally on routine obstetric ultrasonography or at birth, and is frequently surgically removed in infancy. In older patients, careful examination for surgical scar remnants along the ulnar or fibular borders, along with a detailed birth history, is essential for documenting this feature.[2]

Minor Criteria

Eight minor criteria are recognized in the 2026 framework: urine concentration defects at any age, or chronic urinary retention in adults (not counted separately when CAKUT or CKD is already counted); brachydactyly or syndactyly (approximately 56%); hearing loss, predominantly conductive (approximately 11%); laterality defects (approximately 1%); anosmia or hyposmia (approximately 41%); dental anomalies; craniofacial dysmorphisms; and metabolic dysfunction-associated steatotic liver disease (MASLD, not counted separately when obesity is already counted).[2]

Age-Dependent Presentation

The clinical phenotype of BBS evolves substantially across the lifespan. In the prenatal period, sonographic findings may include postaxial polydactyly and renal hyperechogenicity. In the neonatal period, polydactyly and genitourinary anomalies are frequently the presenting features. Obesity and hyperphagia typically manifest by 1 to 2 years of age. Retinal dystrophy becomes functionally evident in mid-childhood, often after the diagnosis of polydactyly and obesity has prompted closer surveillance. Adolescents and adults face compounding morbidity from progressive visual impairment, advancing renal disease, hypogonadism, and metabolic complications, including type 2 diabetes and dyslipidemia.[8]

Evaluation

Diagnostic Algorithm 

Per the 2026 consensus algorithm, all patients with clinical suspicion of BBS, defined as the presence of 1 or more characteristic clinical manifestations or a positive family history, should undergo both clinical evaluation and molecular genetic testing where available. A clinical diagnosis is established when a patient meets 4 major criteria or 3 major criteria plus 2 minor criteria. When clinical criteria are met, genetic confirmation is not required to establish the diagnosis. However, molecular testing remains valuable for management decisions, family planning, and access to targeted therapies (see Image. Bardet-Biedl Syndrome Diagnostic Algorithm).[2]

Genetic Testing and Interpretation

Molecular genetic testing is strongly recommended for all patients, including those who already meet clinical criteria, because the results guide treatment eligibility, inform genetic counseling, and support clinical trial enrollment. Next-generation sequencing panels that include all confirmed BBS-associated genes are the preferred testing modality. Whole-exome or whole-genome sequencing may be considered when panel testing is inconclusive. A positive genetic result is defined as biallelic pathogenic or likely pathogenic variants in a recognized BBS gene, and when combined with at least 1 major clinical criterion, establishes the diagnosis.

An inconclusive result occurs when testing identifies biallelic pathogenic or likely pathogenic variants together with a variant of uncertain significance (VUS), biallelic VUS, or a single heterozygous pathogenic or likely pathogenic variant. A negative result is defined as no variants of likely relevance identified. An inconclusive or negative genetic result does not exclude BBS, because approximately 10% to 20% of patients with a confirmed clinical diagnosis do not have an identified pathogenic genotype on currently available testing. Variant classifications should be reviewed periodically, since reclassification of variants over time, particularly the reclassification of a VUS to pathogenic or likely pathogenic, may convert an inconclusive result into a diagnostic one.[2][6]

Ophthalmologic Evaluation

Formal ophthalmologic assessment at diagnosis should include electroretinography, optical coherence tomography, fundus autofluorescence imaging, and visual field testing. Electroretinography can demonstrate reduced or absent rod and cone responses before patients report subjective visual symptoms and is therefore central to early diagnosis and prognostic counseling. Annual ophthalmologic surveillance is recommended, with the frequency and specific testing modalities individualized based on age and disease stage. Low-vision rehabilitation and orientation-and-mobility services should be introduced early in patients with progressive visual loss.[1] 

Renal Evaluation

Renal ultrasonography at diagnosis is used to document structural anomalies, including cysts, dysplasia, and collecting-system abnormalities. Baseline and annual laboratory evaluation should include serum creatinine, cystatin C, estimated glomerular filtration rate (eGFR), urinalysis with microscopy, and urine protein-to-creatinine ratio. Blood pressure monitoring is essential, as hypertension is common and contributes to CKD progression. Early referral to pediatric or adult nephrology is recommended for patients with structural anomalies, reduced eGFR, proteinuria, or hypertension.[8] 

Metabolic, Endocrine, Cardiac, and Neurodevelopmental Evaluation

Fasting glucose, hemoglobin A1c, fasting lipid panel, liver function tests, and thyroid function should be assessed at diagnosis and monitored regularly to identify and manage metabolic complications, including type 2 diabetes, dyslipidemia, and metabolic dysfunction-associated steatotic liver disease. Gonadal function should be evaluated with luteinizing hormone (LH), follicle-stimulating hormone (FSH), and morning total testosterone in males, and with pelvic ultrasonography in females. Clinical findings and pubertal stage should guide any additional evaluation of female hormones. 

Baseline echocardiography is recommended in all patients at diagnosis to screen for congenital structural heart disease, with subsequent imaging guided by symptoms and initial findings. Formal neuropsychological and developmental assessment should be performed in all pediatric patients, including standardized screening for autism spectrum disorder. Repeat assessments at key developmental and educational transitions are recommended to support individualized education planning and to identify emerging behavioral or psychiatric comorbidities.[5]

Treatment / Management

Setmelanotide (Imcivree)

Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, is the first and currently only FDA-approved pharmacotherapy for obesity management in BBS. Setmelanotide is approved for patients 2 years and older with obesity attributable to BBS, following the December 2024 age expansion from the prior indication of 6 years and older, which was originally granted in June 2022. In the pivotal phase 3 trial, setmelanotide produced a mean BMI reduction of approximately 7.9% at 52 weeks in the open-label period, and a 4.6% reduction compared with a 0.1% reduction for placebo during the 14-week double-blind stage, along with statistically significant reductions in hunger scores.[4](A1)

Mechanistically, setmelanotide directly targets the underlying MC4R pathway impairment. Restoration of agonist activity at the hypothalamic MC4R bypasses the upstream leptin-melanocortin signaling defect that drives hyperphagia in BBS. Common adverse effects include skin hyperpigmentation (attributable to off-target MC1R agonism), injection site reactions, nausea, headache, and diarrhea. The prescribing information includes warnings for serious psychiatric adverse events, including depression and suicidal ideation, and patients should be monitored accordingly during treatment (see Image. Setmelanotide Mechanism of Action in Bardet-Biedl Syndrome).[9](B3)

Obesity and Metabolic Management

Comprehensive obesity management in BBS requires an interprofessional approach. Dietary counseling and behavioral strategies should be tailored to BBS-associated hyperphagia, with attention to structured mealtimes, environmental modifications to limit unsupervised access to food, and family-based behavioral interventions. Physical activity programming should be adapted for visual impairment, balance difficulties, and orthopedic considerations. Bariatric surgery has been reported in small case series with variable outcomes, and given the underlying neurobiological drive for hyperphagia, durable weight loss after surgery alone is often limited. An individualized risk-benefit assessment, with input from an interprofessional obesity team, is recommended.[5]

Renal Management

Renal disease in BBS is comanaged with nephrology. Hypertension should be identified and treated promptly, with renin-angiotensin-aldosterone system (RAAS) inhibition using an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), with the latter preferred in the setting of proteinuria. Patients should be monitored for progression of CKD with periodic eGFR and urinary albumin assessment, and timely planning for kidney replacement therapy should be initiated when appropriate. Renal transplantation outcomes in BBS are reported to be comparable to those in other genetic nephropathies, although recipients require careful posttransplant management of obesity and metabolic comorbidities.[8]

Ophthalmologic Management

Currently, no disease-modifying therapy has been approved for BBS-associated retinal dystrophy. Supportive care, including low-vision aids, orientation and mobility training, educational accommodations, and early connection with vision rehabilitation services, is central to preserving function and quality of life. Investigational gene therapy is in early clinical development. AXV-101 (Axovia Therapeutics), an AAV9-based gene therapy delivering a codon-optimized BBS1 transgene, has received FDA Orphan Drug and Rare Pediatric Disease designations. A first-in-human, open-label, dose-escalation Phase 1/2 trial (AXIS; NCT07269665) was registered in early 2026 to evaluate safety, tolerability, and pharmacodynamics in patients with biallelic BBS1 pathogenic variants and retinal degeneration.[1](B3)

Endocrine and Reproductive Management

Confirmed hypogonadotropic hypogonadism is managed with sex hormone replacement therapy, individualized to the patient's age, pubertal status, and reproductive goals. Type 2 diabetes mellitus is managed per current guidelines, with consideration of agents that offer cardiorenal benefits, eg, sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, when appropriate for the individual patient. Dyslipidemia, metabolic dysfunction-associated steatotic liver disease, and thyroid dysfunction should be screened for and managed in parallel.[3] (B3)

Differential Diagnosis

Several conditions share overlapping features with BBS and must be distinguished through careful clinical evaluation and molecular genetic testing. BBS also has significant genetic and clinical overlap with other ciliopathies, and the possibility of allelic disorders should be considered when variants in BBS-associated genes are identified.[2]

Alström syndrome is an autosomal recessive ciliopathy caused by biallelic pathogenic variants in ALMS1. This syndrome presents with rod-cone retinal dystrophy, childhood obesity, sensorineural hearing loss, dilated cardiomyopathy, and severe insulin resistance. Alström syndrome is distinguished from BBS by the presence of cardiomyopathy and hearing loss, the absence of postaxial polydactyly, and typically preserved cognitive function. 

Laurence-Moon syndrome is now considered a distinct entity from BBS, characterized by progressive spastic paraplegia rather than polydactyly, and has been associated with biallelic variants in PNPLA6. The historical eponym "Laurence-Moon-Bardet-Biedl syndrome" reflects earlier conflation of the 2 conditions and is no longer recommended. Prader-Willi syndrome presents with neonatal hypotonia and feeding difficulties, followed in early childhood by hyperphagia, obesity, hypogonadism, and intellectual disability. Prader-Willi syndrome is caused by loss of paternally expressed genes in the 15q11-q13 region and is confirmed by DNA methylation analysis. Retinal dystrophy and polydactyly are not features that distinguish it from BBS.

McKusick-Kaufman syndrome (MKKS) is caused by biallelic variants in the MKKS gene, also designated BBS6, and is therefore an allelic disorder of BBS. MKKS is characterized by postaxial polydactyly, hydrometrocolpos, congenital heart defects, and genitourinary malformations, while retinal dystrophy, obesity, and neurodevelopmental impairment are typically absent. This distinction is clinically important when biallelic MKKS/BBS6 variants are identified, because the same genotype can produce either MKKS or BBS, depending on the variant and modifying factors. Longitudinal follow-up may be required before the phenotype is clear, particularly in infancy.[2]

Joubert syndrome is distinguished by cerebellar vermis hypoplasia producing the pathognomonic "molar tooth sign" on brain MRI, along with hypotonia, oculomotor apraxia, and abnormal breathing patterns in infancy. Renal and retinal features overlap in BBS, and several ciliary genes are shared between the 2 conditions, reinforcing the value of molecular genetic testing in ambiguous presentations. Cohen syndrome is caused by biallelic variants in VPS13B and features intellectual disability, characteristic facial dysmorphism, truncal obesity, microcephaly, and intermittent neutropenia. The retinal dystrophy seen in Cohen syndrome differs in pattern from the rod-cone dystrophy of BBS, and postaxial polydactyly is not a feature.[1]

Prognosis

The prognosis of BBS is determined largely by the severity and trajectory of renal disease, which remains the leading cause of premature mortality. Chronic kidney disease progresses to kidney failure in a meaningful proportion of patients, with approximately 6% to 7% ultimately requiring kidney replacement therapy in the form of dialysis or transplantation.[2] Progressive retinal dystrophy follows a near-universal course, and most patients reach legal blindness between the second and fourth decades of life.

Cardiovascular morbidity related to obesity, hypertension, dyslipidemia, and metabolic syndrome contributes meaningfully to long-term outcomes and is increasingly recognized as a target for early intervention. Neurodevelopmental trajectories are variable. Intellectual disability and behavioral comorbidities are common, but many individuals achieve meaningful functional independence with timely educational support, behavioral therapy, and family-centered care. 

The availability of setmelanotide offers the potential to mitigate the metabolic and quality-of-life consequences of hyperphagia and early-onset obesity when initiated early in the disease course. However, long-term outcome data on renal, cardiovascular, and survival endpoints are not yet available, and clinical registries eg, CRIBBS and the European BBS networks, will be essential to define these outcomes over time.[1][8]

Complications

BBS is associated with multiorgan complications that accumulate across the lifespan. The most consequential and life-limiting of these is progressive CKD, which may advance to kidney failure and remains the primary cause of premature mortality. Vision loss progressing to legal blindness profoundly affects quality of life, educational attainment, vocational opportunities, and overall functional independence and warrants early integration of low-vision rehabilitation and assistive services.

Obesity-related complications are common and frequently develop in childhood or adolescence. These include type 2 diabetes, metabolic syndrome, dyslipidemia, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease (MASLD), which may progress silently to hepatic fibrosis in a subset of patients. Hypertension is common and accelerates both cardiovascular and renal disease progression.

Congenital heart defects, including atrial and ventricular septal defects, patent ductus arteriosus, and left ventricular hypertrophy, are recognized cardiac associations and underscore the rationale for baseline echocardiography at diagnosis. Reproductive complications include infertility, hypogonadotropic hypogonadism, and structural genitourinary anomalies that may require surgical management. Neuropsychiatric manifestations, including anxiety, depression, features of autism spectrum disorder, obsessive-compulsive traits, and emotional dysregulation, are increasingly recognized as core contributors to social functioning and quality of life, and should be addressed proactively as part of comprehensive care.[5][1]